Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin

Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.

The use of intravenous infusions of immunoglobulin in the treatment of Guillain-Barre syndrome has become widespread. However, this treatment is not without morbidity. We describe an acute encephalopathy occurring in a patient receiving intravenous immunoglobulin infusions for Guillain-Barre syndrome. A 55 year old woman was admitted with a four week history of malaise and occasional rigors and...

Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G

Intravenous immunoglobulin (IVIg) products from different pharmaceutical companies vary in composition, in part because of the selected blood donors and production process. N-glycosylation of the Fc-portion of IgG varies between blood donors and may influence both the side-effects and therapeutic effectiveness of IVIg. At present, the variation in Fc N-glycosylation between IVIg products has no...

Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome.

Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin

BACKGROUND Guillain-Barré syndrome (GBS) is an autoimmune condition characterized by peripheral neuropathy. The pathogenesis of GBS is not fully understood, and the mechanism of how intravenous immunoglobulin (IVIG) cures GBS is ambiguous. Herein, we investigated lymphocyte subsets in patients with two major subtypes of GBS (acute inflammatory demyelinating polyneuropathy, AIDP, and acute motor...

Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome

INTRODUCTION The aim of the study is to compare efficacy of IvIg versus PE in treatment of mechanically ventilation adults with GBS in intensive care unit. METHODS It is a prospective, non randomized study, realized in a medical ICU from 2006 to 2010. We included all patients with GBS who required mechanical ventilation (MV). We defined two groups: group 1 (group treated by IvIg: 0.4 g/kg/day...